Pfizer gets option to MedGenesis' Parkinson's candidate and technology; deal terminated
Executive Summary
Neurology-focused MedGenesis Therapeutix Inc. granted Pfizer Inc. the option to license exclusive global rights to its glial cell line-derived neurotrophic factor (GDNF) protein and Convection-Enhanced Delivery (CED) technology for use in developing Parkinson's disease therapies.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Site Specific
-
Drug Delivery
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice